MLLT3

Across TCGA pan-cancer cohorts, MLLT3 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated MLLT3 data layer compared with 19 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher MLLT3 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated MLLT3 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

OV, LIHC, and UCEC are the cancer types where MLLT3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	OS	Median	All	0.244	0.690	.006	18	view →
LIHC	DFS	Median	II,III,IV	0.044	0.427	<.001	15	view →
UCEC	DFS	Median	II,III,IV	0.931	0.304	.011	14	view →
ESCA	OS	Median	II,III,IV	0.321	0.685	.035	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

MLLT3–OV (OS)

Open the OV breakdown →